The role of caspase-8 in resistance to cancer chemotherapy

Drug Resistance Updates

Volumn 4, Issue 5, 2001, Pages 293-296

  Kim, Peter K M ^a   Mahidhara, Raja ^a   Seol, Dai Wu ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 8; CASPASE INHIBITOR; CISPLATIN; CYTARABINE; CYTOTOXIC AGENT; DOXORUBICIN; ETOPOSIDE; FLICE INHIBITORY PROTEIN; GEMCITABINE; METHOTREXATE; PACLITAXEL; PROTEIN BCL 2; TOPOTECAN;

APOPTOSIS; CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CYTOTOXICITY; ENZYME ACTIVATION; HUMAN; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SENSITIZATION; SHORT SURVEY; SIGNAL TRANSDUCTION;

EID: 0035736492     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1054/drup.2001.0223     Document Type: Article

References (51)

1. Caspases: Enemies within
2. Dysregulation of apoptosis in cancer
3. Two CD95 (APO-/Fas) signaling pathways
4. The biochemistry of apoptosis
5. Death receptors: Signaling and modulation
6. FADD/MORTI is a common mediator of CD95 (Fas/APO-) and tumor necrosis factor receptor-induced apoptosis
7. The TNF receptor-associated protein TRADD signals cell death and NF-kappa B activation
8. Cytotoxicity-dependent APO-(Fas/CD95)-associated protein form a death-inducing signaling complex (DISC) with the receptor
9. Autoproteolytic activation of pro-caspases by oligomerization
10. An induced proximity model for caspase-8 activation
11. Membrane oligomerization and cleavage activates the caspase-8 (FLICE/MACHalphaI) death signal
12. Apoptosis by death factor
13. CD95's deadly mission in the immune system
14. Apoptotic pathways: Paper wraps stone blunts scissors
15. Caspase-8 activation and bid cleavage contribute to MCF7 cellular execution in a caspase-3-dependent manner during staurosporine-mediated apoptosis
16. BCL-2 gene family and the regulation of programmed cell death
17. Involvement of the CD-95 (APO-/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells
18. Deficient activation of the CD95 (APO-/Fas) system in drug-resistant cells
19. Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis
20. Signaling events triggered by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL): Caspase-8 is required for TRAIL-induced apoptosis
21. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5
22. Helenalin triggers a CD95 death receptor-independent apoptosis that is not affected by overexpression of Bcl-x(L) or Bcl-2
23. Tumor necrosis factor-related apoptosis-inducing ligand retains its apoptosis-inducing capacity on Bcl-2- or Bcl-xL-overexpressing chemotherapy-resistant tumor cells
24. Pediatric rhabdomyosarcoma cell lines are resistant to Fas-induced apoptosis and highly sensitive to TRAIL-induced apoptosis
25. Comparison of apoptosis in wild-type and Fas-resistant cells: Chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions
26. Chemotherapeutic drug-induced apoptosis in human leukaemic cells is independent of the Fas (APO-/CD95) receptor/ligand system
27. Drug-induced apoptosis in lung cancer cells is not mediated by the Fas/FasL (CD95/APO) signaling pathway
28. Distinct caspase cascades are initiated in receptor-mediated and chemical-induced apoptosis
29. Chemotherapy triggers apoptosis in a caspase-8-dependent and mitochondria-controlled manner in the non-small cell lung cancer cell line NCI-H460
30. Cisplatin (CDDP) specifically induces apoptosis via sequential activation of caspase-8, -3 and -6 in osteosarcoma
31. Involvement of CD95-independent caspase 8 activation in arsenic trioxide-induced apoptosis
32. The (patho) physiological functions of the MRP family
33. Fas-mediated apoptosis in neuroblastoma requires mitochondrial activation and is inhibited by FLICE inhibitor protein and Bcl-2
34. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN
35. Resistance to TRAIL-induced apoptosis in primitive neuroectodermal brain tumor cells correlates with a loss of caspase-8 expression
36. Role of specific apoptotic pathways in the restoration of paclitaxel-induced apoptosis by valspodar in doxorubicin-resistant MCF-7 breast cancer cells
37. A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma
38. Inhibition of death receptor signals by cellular FLIP
39. The role of c-FLIP in modulation of CD95-induced apoptosis
40. Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein
41. Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma
42. The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors
43. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells
44. Molecular determinants of response to TRAIL in killing of normal and cancer cells
45. BAR An apoptosis regulator at the intersection of caspases and Bcl-2 family proteins
46. Does resistance to apoptosis affect clinical response to antitumor drugs?
47. Apoptosis: Mediator or mode of cell killing by anticancer agents?
48. Apoptosis is critical for drug response in vivo
49. Interferon-gamma treatment elevates caspase-8 expression and sensitizes human breast tumor cells to a death receptor-induced mitochondria-operated apoptotic program
50. Lactacystin activates FLICE (caspase 8) protease and induces apoptosis in Fas-resistant adult T-cell leukemia cell lines
51. Sensitization for death-receptor or drug-induced apoptosis by restoration of caspase-8 expression through demethylation or caspase-8 gene transfer